# A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Source: https://onco.cc/trials/nct07541079/  
OnCo record `nct07541079` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Giredestrant in advanced solid tumours, run by Genentech, Inc., now recruiting.

## Summary

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) is a phase 3 interventional study registered as NCT07541079 by Genentech, Inc., with 300 participants planned, started 2026-08-25 and due to reach its primary completion in 2032-06-30. Interventions recorded: Giredestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07541079
- Phase: 3
- Setting: A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy
- Sponsor: Genentech, Inc.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07541079: https://clinicaltrials.gov/study/NCT07541079

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Giredestrant](https://onco.cc/drugs/giredestrant/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07541079.json